

Perspective

# Reconsidering Vitamin D Supplementation in Pulmonary Disease: The Case for Targeted Respiratory Delivery

Kevin D. Schichlein, PhD<sup>1</sup> Ilona Jaspers, PhD<sup>2</sup> M. Bradley Drummond, MD, MHS<sup>3</sup>

## Abstract

Despite compelling epidemiological evidence linking vitamin D deficiency to adverse outcomes in chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, randomized controlled trials have consistently failed to demonstrate clinically meaningful benefits from oral vitamin D supplementation. This disconnect between observational associations and interventional evidence represents a significant paradox in pulmonary medicine. Recent meta-analyses have found limited protective or therapeutic effects of oral supplementation on exacerbation rates, lung function, hospitalizations, or quality-of-life measures. We propose that this therapeutic failure reflects not a lack of vitamin D's efficacy but rather a fundamental limitation in the route of delivery.

Oral vitamin D supplementation undergoes hepatic metabolism and systemic dilution before reaching respiratory tissues. High expression of cytochrome P450 family 24 subfamily A member 1, the vitamin D-inactivating enzyme, in pulmonary vasculature suggests that orally delivered vitamin D may be degraded before reaching the lung lumen. The respiratory epithelium possesses complete machinery for vitamin D activation, and vitamin D receptors are expressed throughout airway epithelial and immune cells, making direct pulmonary delivery mechanistically feasible. Preclinical studies demonstrate that nebulized or inhaled vitamin D reduces inflammation, protects epithelial barrier function, and improves lung function in murine models of respiratory disease without producing off-target systemic effects or hypercalcemia.

Direct lung delivery of vitamin D represents an unexplored therapeutic strategy that could transform management of chronic respiratory diseases, like COPD, by achieving local therapeutic concentrations while minimizing systemic exposure. Clinical trials investigating safety, dosing optimization, and efficacy are warranted.

1. Curriculum in Toxicology and Environmental Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
2. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
3. Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

## Abbreviations:

**COPD**=chronic obstructive pulmonary disease; **CYP2R1**=cytochrome P450 family 2 subfamily R member 1; **CYP24A1**=cytochrome P450 family 24 subfamily A member 1; **CYP27A1**=cytochrome P450 family 27 subfamily A member 1; **CYP27B1**=cytochrome P450 family 27 subfamily B member 1; **HP**=hypersensitivity pneumonitis

## Funding Support:

None

## Citation:

Schichlein KD, Jaspers I, Drummond MB. Reconsidering vitamin D supplementation in pulmonary disease: the case for targeted respiratory delivery. *Chronic Obstr Pulm Dis*. 2026;13(3):249-254.  
doi: <https://doi.org/10.15326/jcopdf.2025.0713>

## Publication Dates:

**Date of Acceptance:** March 3, 2026

**Published Online Date:** March 31, 2026

## Address correspondence to:

Ilona Jaspers, PhD  
Department of Pediatrics  
University of North Carolina at Chapel Hill  
Chapel Hill, NC  
Phone: (919) 966-8657  
Email: [ilona\\_jaspers@med.unc.edu](mailto:ilona_jaspers@med.unc.edu)

## Keywords:

vitamin D; inhalation; asthma; cystic fibrosis; COPD

## Introduction

Since the incidence of asthma and allergy began rising in the late 1900s, much research has focused on understanding the causes behind this phenomenon. Initial evidence from epidemiological studies found increased asthma prevalence in developed countries, leading to the idea that increased time indoors led to decreased sunlight-driven vitamin D synthesis and lower vitamin D levels.<sup>1</sup> Since this initial idea, numerous studies have been conducted on the relationship between vitamin D and asthma, now expanding to other respiratory diseases, like chronic obstructive pulmonary disease (COPD), infections, and environmental exposures. However, despite compelling epidemiological evidence linking low vitamin D levels to increased exacerbations and reduced lung function in COPD, asthma, cystic fibrosis, and other respiratory pathologies, randomized controlled trials have consistently failed to demonstrate clinically meaningful benefits from oral vitamin D supplementation. Meta-analyses across lung diseases reveal a disconnect between observational associations and interventional evidence, with minimal effects predominating across study designs, dosing regimens, and sample sizes.

## The Vitamin D Paradox

The failure of vitamin D supplementation to improve clinical outcomes represents one of the most significant examples of the "vitamin D paradox" in respiratory medicine, where strong epidemiological associations fail to translate into therapeutic benefits. Across trials, oral vitamin D supplementation has shown no consistent effects on lung function, exacerbation rates, hospitalizations, or quality-of-life measures in respiratory disease patients.<sup>2-6</sup> Observational studies across conditions consistently demonstrate strong associations between vitamin D deficiency and adverse outcomes.<sup>7</sup> Patients with COPD with vitamin D deficiency show higher hospitalization rates and more frequent exacerbations. In asthma, low vitamin D levels correlate with increased exacerbation rates, reduced lung function, and poor symptom control.<sup>8</sup> Cystic fibrosis patients, who experience near-universal vitamin D deficiency due to malabsorption, exhibit associations between low vitamin D and worse respiratory outcomes. However, in supplementation studies, the results were overwhelmingly negative.<sup>9</sup> A 2024 Cochrane review for COPD found little to no changes in exacerbation rates, lung capacity, or quality of life with supplementation.<sup>10</sup> Similarly, a 2023 updated Cochrane review for asthma reversed the conclusions of their 2016 review, finding no protective effects against exacerbations.<sup>8</sup>


The evolution of lung disease trial evidence illustrates the broader pattern of oral vitamin D supplementation failures. Early promise from smaller studies gave way to

negative results from large, well-designed trials. Cystic fibrosis presents the most compelling case for vitamin D supplementation, with 90% of patients experiencing vitamin D deficiency due to malabsorption.<sup>5</sup> Yet clinical trials consistently demonstrate that correcting circulating levels of vitamin D deficiency fails to produce clinical benefits. Across all 3 diseases, oral vitamin D supplementation failed to improve the most clinically relevant outcomes. Lung function measures, including forced expiratory volume in 1 second and forced vital capacity, showed no consistent improvements, exacerbation rates remained unchanged, and hospitalization rates and quality-of-life scores were similarly unaffected. Even in severely deficient populations, benefits are modest and inconsistent. Meta-analyses of COPD and asthma trials found protective effects primarily in patients with baseline levels <25nmol/L, but this represented a small subset of study participants.<sup>2,6</sup>

## Oral Supplementation Versus Direct Delivery to the Airway Epithelium

Despite extensive documentation of vitamin D deficiency in pulmonary disease populations and compelling mechanistic evidence from *in vitro* and *in vivo* studies, systematic reviews and meta-analyses have consistently failed to demonstrate meaningful clinical benefits from oral vitamin D supplementation across respiratory conditions. The numerous clinical disappointments necessitate critical re-examination. We posit that the fundamental limitation lies not in vitamin D's therapeutic potential but in our approach to its delivery. Oral vitamin D supplementation is subject to hepatic metabolism, systemic dilution, and most notably, potential inactivation before reaching target tissue in the respiratory tract. A recent study of vitamin D-related genes in human lung tissue found that cytochrome P450 family 24 subfamily A member 1 (CYP24A1), the enzyme responsible for inactivating the biologically active form of vitamin D to the form that is eventually excreted, was highly expressed in pulmonary vascular endothelial cells.<sup>11</sup> This suggests that oral vitamin D may be inactivated before reaching the lung lumen and thus, ineffective in exerting therapeutic effects in the lungs at clinically relevant levels.

Therefore, direct delivery of vitamin D to the airway epithelium through topical or inhaled administration may provide a more effective route for treating lung disease. The respiratory epithelium possesses complete machinery for vitamin D metabolism, including expression of cytochrome P450 family 27 subfamily B member 1 (CYP27B1) for local calcitriol synthesis and expression of vitamin D receptors across airway epithelial and immune cells (Figure 1).<sup>12</sup> The biologically active form of vitamin D, calcitriol, exerts pleiotropic effects within the airways, including upregulation of antimicrobial peptides such as cathelicidin and  $\beta$ -defensins, enhancement of epithelial

**Figure 1. Vitamin D Oral Supplementation Versus Inhaled Delivery**

CYP24A1=cytochrome P450 family 24 subfamily A member 1; CYP27A1=cytochrome P450 family 27 subfamily A member 1; CYP27B1=cytochrome P450 family 27 subfamily B member 1; CYP2R1=cytochrome P450 family 2 subfamily R member 1

barrier function through tight junction proteins, modulation of inflammatory cascades via nuclear factor- $\kappa$ B and mitogen-activated protein kinase pathways, and augmentation of antioxidant defenses. Vitamin D's capacity to bolster these defenses while simultaneously modulating inflammatory responses positions it as an ideal therapeutic candidate for respiratory conditions characterized by oxidative stress and inflammation.

Several recent preclinical studies have explored this approach *in vivo*, producing promising results. Serré et al demonstrated that nebulized vitamin D reduced inflammatory cell infiltration and protected epithelial barrier function in lipopolysaccharide-exposed mice, without altering systemic vitamin D levels.<sup>13</sup> This proof-of-concept study highlights the potential for achieving local therapeutic effects while minimizing systemic exposure. Another group has also published several studies investigating inhaled vitamin D as a method to restore local vitamin D levels and to treat hypersensitivity pneumonitis (HP) and pulmonary fibrosis in murine models, finding beneficial effects against HP-induced collagen deposition, epithelial-mesenchymal transition, and lung function decrements.<sup>14-16</sup> Vitamin D dry powder formulations have also been explored as an adjunct therapeutic for tuberculosis.<sup>17,18</sup> Additionally, pulmonary administration of vitamin D treatment in murine models of COPD induced alveolar regeneration and

improved lung function.<sup>19,20</sup> Nasal delivery of vitamin D has also shown promise in models of sinonasal disease and infection.<sup>21-24</sup> *In vitro* studies using primary airway cells at air-liquid interface have shown that apical application of vitamin D enhances antimicrobial peptide expression, reduces pathogen-induced inflammation, and can protect against pollutant-induced oxidative stress, suggesting direct epithelial effects independent of systemic metabolism.<sup>25,26</sup> The potential benefits of inhaled vitamin D extend across the spectrum of chronic respiratory diseases, being able to combat chronic inflammation and oxidative stress as well as bolstering antimicrobial defenses. Additionally, the *in vivo* studies discussed seem to show no evidence of adverse effects such as hypercalcemia, and in several studies, did not lead to significant changes in circulating vitamin D levels.<sup>27,28</sup> Key limitations to the existing studies are the focus on *ex vivo* and animal studies, with most encompassing short exposure periods.

## Conclusions

To the best of our knowledge, no clinical trials have investigated pulmonary delivery of vitamin D in individuals with chronic lung diseases, like COPD, despite promising preclinical results. As such, future work should establish human safety data (especially in the context of

prolonged exposure), dosing and delivery optimization, pharmacokinetics/pharmacodynamics, and clinical utility. A challenge of pulmonary drug delivery is that most agents are fat soluble (and thus, poorly water soluble) limiting drug dosage. Given that vitamin D is fat-soluble, further preclinical work is needed on formulation and in vivo effects in relevant animal models.<sup>29</sup> Additionally, more extensive work on the pharmacokinetics of oral vitamin D, especially in the pulmonary compartment, may help elucidate why correction of circulating vitamin D levels does not lead to clinical benefits. To date, work on pulmonary delivery has largely focused on in vitro and animal studies, therefore, we hope this piece leads to further research and discussion on this topic and eventual translation to clinical utility.

The disconnect between vitamin D's mechanistic promise and clinical disappointment in respiratory disease reflects a fundamental mismatch between therapeutic target and delivery method. By reconceptualizing vitamin D as a local respiratory therapeutic rather than a systemic supplement, we can potentially unlock its therapeutic benefits. As we continue to face challenges from air pollution, emerging respiratory pathogens, and the growing burden of chronic lung disease, evaluating vitamin D through the lens of pulmonary delivery could offer a targeted approach to enhance pulmonary defense mechanisms. This delivery strategy may also benefit other vitamins and nutraceuticals implicated in lung disease such as omega-3 fatty acids and vitamin E.<sup>30-35</sup> Direct pulmonary delivery of vitamins and nutrients presents an under-explored and promising approach for treating lung disease and warrants further investigation.

## Acknowledgements

**Author contributions:** All authors contributed to writing and revisions of the piece and approved the final version to be published.

**Other acknowledgements:** Figure created in BioRender. Schichlein, K. (2025) <https://BioRender.com/q1ceqev>

## Declaration of Interest

The authors report no conflicts of interest related to this work.

## References

1. Litonjua AA, Weiss ST. Is vitamin D deficiency to blame for the asthma epidemic? *J Allergy Clin Immunol.* 2007;120(5):1031-1035. <https://doi.org/10.1016/j.jaci.2007.08.028>
2. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. *Thorax.* 2019;74(4):337-345. <https://doi.org/10.1136/thoraxjnl-2018-212092>
3. Mathyssen C, Gayan-Ramirez G, Bouillon R, Janssens W. Vitamin D supplementation in respiratory diseases: evidence from randomized controlled trials. *Pol Arch Intern Med.* 2017;127(11):775-784. <https://doi.org/10.20452/pamw.4134>
4. Gilbert CR, Arum SM, Smith CM. Vitamin D deficiency and chronic lung disease. *Can Respir J.* 2009;16(3):75-80. <https://doi.org/10.1155/2009/829130>
5. Farahbakhsh N, Fatahi S, Shirvani A, et al. Vitamin D deficiency in patients with cystic fibrosis: a systematic review and meta-analysis. *J Health Popul Nutr.* 2024;43:11. <https://doi.org/10.1186/s41043-024-00499-2>
6. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. *Lancet Respir Med.* 2017;5(11):881-890. [https://doi.org/10.1016/S2213-2600\(17\)30306-5](https://doi.org/10.1016/S2213-2600(17)30306-5)
7. Afzal M, Kazmi I, Al-Abbasi FA, et al. Current overview on therapeutic potential of vitamin D in inflammatory lung diseases. *Biomedicines.* 2021;9(12):1843. <https://doi.org/10.3390/biomedicines9121843>
8. Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. *Cochrane Database Syst Rev.* 2023;(2):CD011511. <https://doi.org/10.1002/14651858.CD011511.pub3>
9. Juhász ME, Varannai O, Németh D, et al. Vitamin D supplementation in patients with cystic fibrosis: a systematic review and meta-analysis. *J Cyst Fibros.* 2021;20(5):729-736. <https://doi.org/10.1016/j.jcf.2020.12.008>
10. Williamson A, Martineau AR, Jolliffe D, et al. Vitamin D for the management of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2024;(9):CD013284. <https://doi.org/10.1002/14651858.CD013284.pub2>
11. Mathyssen C, Aelbrecht C, Serré J, et al. Local expression profiles of vitamin D-related genes in airways of COPD patients. *Respir Res.* 2020;21:137. <https://doi.org/10.1186/s12931-020-01405-0>
12. Schruppf JA, van der Does AM, Hiemstra PS. Impact of the local inflammatory environment on mucosal vitamin D metabolism and signaling in chronic inflammatory lung diseases. *Front Immunol.* 2020;11:1433. <https://doi.org/10.3389/fimmu.2020.01433>
13. Serré J, Mathyssen C, Ajime TT, et al. Local nebulization of 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> attenuates LPS-induced acute lung inflammation. *Respir Res.* 2022;23:76. <https://doi.org/10.1186/s12931-022-01997-9>
14. Lemieszek MK, Chojnacki M, Paśnik I, et al. The first step for understanding the molecular mechanism of the antifibrotic effect of inhaling 25(OH)-vitamin D<sub>3</sub> and 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> in the murine model of hypersensitivity pneumonitis. *Front Pharmacol.* 2025;16:1610165. <https://doi.org/10.3389/fphar.2025.1610165>
15. Chojnacki M, Anisiewicz J, Leśniowska I, Lemieszek MK. Inhalation with vitamin D<sub>3</sub> metabolites—a novel strategy to restore vitamin D<sub>3</sub> deficiencies in lung tissue. *Appl Sci (Basel).* 2023;13(19):10672. <https://doi.org/10.3390/app131910672>
16. Lemieszek MK, Chojnacki M, Paśnik I, et al. Beneficial impact of inhaled 25(OH)-vitamin D<sub>3</sub> and 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> on pulmonary response in the murine model of hypersensitivity pneumonitis. *Int J Mol Sci.* 2024;25(19):10289. <https://doi.org/10.3390/ijms251910289>
17. Reddy DVS, Sofi HS, Roy T, et al. Macrophage-targeted versus free calcitriol as host-directed adjunct therapy against Mycobacterium tuberculosis infection in mice is bacteriostatic and mitigates tissue pathology. *Tuberculosis.* 2024;148:102536. <https://doi.org/10.1016/j.tube.2024.102536>
18. Reddy DVS, Shafi H, Bharti R, et al. Preparation and evaluation of low-dose calcitriol dry powder inhalation as host-directed adjunct therapy for tuberculosis. *Pharm Res.* 2022;39:2621-2633. <https://doi.org/10.1007/s11095-022-03360-5>
19. Akita T, Hirokawa M, Yamashita C. The effects of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> on alveolar repair and bone mass in adiponectin-deficient mice. *J Steroid Biochem Mol Biol.* 2020;201:105696. <https://doi.org/10.1016/j.jsbmb.2020.105696>
20. Horiguchi M, Hirokawa M, Abe K, Kumagai H, Yamashita C. Pulmonary administration of 1,25-dihydroxyvitamin D<sub>3</sub> to the lungs induces alveolar regeneration in a mouse model of chronic obstructive pulmonary disease. *J Control Release.* 2016;233:191-197. <https://doi.org/10.1016/j.jconrel.2016.05.006>
21. Langerude L, McQuiston A, Atkinson C, Mulligan JK. Intranasal calcitriol accelerates improvement of sinonasal inflammation and olfactory impairment in mice after cessation of chronic cigarette-smoke exposure. *Int Forum Allergy Rhinol.* 2025;15(7):680-691. <https://doi.org/10.1002/alr.23504>
22. Cho SW, Zhang YL, Ko YK, et al. Intranasal treatment with 1, 25-dihydroxyvitamin D<sub>3</sub> alleviates allergic rhinitis symptoms in a mouse model. *Allergy Asthma Immunol Res.* 2019;11(2):267-279. <https://doi.org/10.4168/aa.2019.11.2.267>
23. Fernandes de Souza WD, Zorzella-Pezavento SFG, Ayupe MC, et al. Lung inflammation induced by inactivated SARS-CoV-2 in C57BL/6 female mice is controlled by intranasal instillation of vitamin D. *Cells.* 2023;12(7):1092. <https://doi.org/10.3390/cells12071092>

- 
24. Gong W, Feng Y, Yan P, et al. Effect of nasal instillation of vitamin D3 on patient with allergic rhinitis symptoms [in Chinese]. *Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*. 2014;28(14):1031-3. <https://pubmed.ncbi.nlm.nih.gov/25330636/>
- 
25. DiFranco KM, Mulligan JK, Sumal AS, Diamond G. Induction of CFTR gene expression by 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub>, 25OH vitamin D<sub>3</sub>, and vitamin D<sub>3</sub> in cultured human airway epithelial cells and in mouse airways. *J Steroid Biochem Mol Biol*. 2017;173:323-332. <https://doi.org/10.1016/j.jsbmb.2017.01.013>
- 
26. Schichlein KD, Masood S, Kim HYH, et al. Aerosolized vitamin D attenuates ozone-induced inflammation and transcriptional responses via membrane antioxidant effects in human bronchial epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2025;329(4):514-523. <https://doi.org/10.1152/ajplung.00233.2025>
- 
27. Taylor SK, Sakurai R, Sakurai T, Rehan VK. Inhaled vitamin D: a novel strategy to enhance neonatal lung maturation. *Lung*. 2016;194:931-943. <https://doi.org/10.1007/s00408-016-9939-3>
- 
28. Bianchi F, Sommariva M, Le Noci V, et al. Aerosol 1,25-dihydroxyvitamin D<sub>3</sub> supplementation: a strategy to boost anti-tumor innate immune activity. *PLoS One*. 2021;16(3):e0248789. <https://doi.org/10.1371/journal.pone.0248789>
- 
29. Sécher T, Bodier-Montagutelli E, Guillon A, Heuzé-Vourc'h N. Correlation and clinical relevance of animal models for inhaled pharmaceuticals and biopharmaceuticals. *Adv Drug Deliv Rev*. 2020;167:148-169. <https://doi.org/10.1016/j.addr.2020.06.029>
- 
30. Tong H. Dietary and pharmacological intervention to mitigate the cardiopulmonary effects of air pollution toxicity. *Biochim Biophys Acta Gen Subj*. 2016;1860(12):2891-2898. <https://doi.org/10.1016/j.bbagen.2016.05.014>
- 
31. Yaeger MJ, Leuenberger L, Shaikh SR, Gowdy KM. Omega-3 fatty acids and chronic lung diseases: a narrative review of impacts from womb to tomb. *J Nutr*. 2025;155(2):453-464. <https://doi.org/10.1016/j.tjnut.2024.10.028>
- 
32. Romieu I, Castro-Giner F, Kunzli N, Sunyer J. Air pollution, oxidative stress and dietary supplementation: a review. *Eur Respir J*. 2007;31(1):179-197. <https://doi.org/10.1183/09031936.00128106>
- 
33. Cook-Mills JM, Averill SH, Lajiness JD. Asthma, allergy and vitamin E: current and future perspectives. *Free Radic Biol Med*. 2022;179:388-402. <https://doi.org/10.1016/j.freeradbiomed.2021.10.037>
- 
34. Whyand T, Hurst JR, Beckles M, Caplin ME. Pollution and respiratory disease: can diet or supplements help? A review. *Respir Res*. 2018;19:79. <https://doi.org/10.1186/s12931-018-0785-0>
- 
35. Schichlein KD, Smith GJ, Jaspers I. Protective effects of inhaled antioxidants against air pollution-induced pathological responses. *Respir Res*. 2023;24:187. <https://doi.org/10.1186/s12931-023-02490-7>
-